DB
NVCR icon

Dmitry Balyasny’s NovoCure NVCR Stock Holding History

Dmitry Balyasny’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.27M Buy
479,999
+468,168
+3,957% +$7.08M 0.01% 1207
2026
Q1 		$129K Sell
11,831
-19,508
-62% -$244K ﹤0.01% 2744
2025
Q4 		$405K Buy
+31,339
New +$402K ﹤0.01% 2613
2025
Q3 		– Sell
-2,270,076
Closed -$40.4M – 3302
2025
Q2 		$40.4M Buy
2,270,076
+634,925
+39% +$11.1M 0.06% 403
2025
Q1 		$29.1M Buy
1,635,151
+566,288
+53% +$12.9M 0.05% 464
2024
Q4 		$31.9M Buy
1,068,863
+229,689
+27% +$4.86M 0.05% 472
2024
Q3 		$13.1M Buy
839,174
+244,176
+41% +$4.43M 0.02% 820
2024
Q2 		$10.2M Buy
594,998
+167,719
+39% +$2.95M 0.02% 879
2024
Q1 		$6.68M Buy
427,279
+110,476
+35% +$1.62M 0.01% 1110
2023
Q4 		$4.73M Sell
316,803
-792,812
-71% -$10.6M 0.01% 1137
2023
Q3 		$17.9M Buy
1,109,615
+250,509
+29% +$7.22M 0.04% 612
2023
Q2 		$35.7M Buy
859,106
+501,077
+140% +$31.1M 0.08% 349
2023
Q1 		$21.5M Buy
+358,029
New +$28.6M 0.05% 484
2022
Q2 		– Sell
-37,593
Closed -$2.83M – 3044
2022
Q1 		$3.12M Sell
37,593
-38,373
-51% -$2.83M 0.01% 1159
2021
Q4 		$5.7M Buy
75,966
+66,614
+712% +$6.69M 0.02% 810
2021
Q3 		$1.09M Buy
+9,352
New +$1.41M ﹤0.01% 1310
2020
Q4 		– Sell
-80,588
Closed -$8.97M – 1585
2020
Q3 		$8.97M Sell
80,588
-280,467
-78% -$22.4M 0.07% 417
2020
Q2 		$21.4M Buy
+361,055
New +$23.7M 0.19% 155
2019
Q3 		– Sell
-20,236
Closed -$1.28M – 1455
2019
Q2 		$1.28M Buy
20,236
+9,189
+83% +$466K 0.01% 1012
2019
Q1 		$532K Buy
+11,047
New +$532K ﹤0.01% 1190
2018
Q4 		– Sell
-9,165
Closed -$480K – 1641
2018
Q3 		$480K Buy
+9,165
New +$365K ﹤0.01% 1396
2018
Q2 		– Sell
-29,036
Closed -$633K – 2039
2018
Q1 		$633K Buy
+29,036
New +$625K ﹤0.01% 1379

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Dmitry Balyasny's NVCR Position: Q2 2026 in Review

Dmitry Balyasny increased its NovoCure (NVCR) stake by 3,957% in Q2 2026, buying an estimated $7.08M and bringing the position to 479,999 shares worth $7.27M. The position accounts for 0.01% of the portfolio, ranked #1207.

Dmitry Balyasny first reported a position in NVCR in Q1 2018 and has held it in 22 quarters since. The position peaked at $40.4M in Q2 2025. 215 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Dmitry Balyasny held 479,999 shares of NovoCure worth $7.27M as of Q2 2026.
  • Dmitry Balyasny bought 468,168 NovoCure shares in Q2 2026, an estimated $7.08M.
  • NovoCure made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1207 holding.
  • Dmitry Balyasny first reported a position in NovoCure in Q1 2018 and has held it in 22 quarters since.
  • Dmitry Balyasny's NovoCure position peaked at $40.4M in Q2 2025.
  • 215 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.